 | | Vol. 6.27 – 29 July, 2022 |
| |
|
|
| Researchers showed that triclosan, a high-volume antimicrobial additive that was detected in human breast milk, could be efficiently transferred by lactation to newborn mice, causing significant fatty liver during the suckling period.
[Nature Communications] |
|
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors suggested that glutamine synthase 2 (GLS2) was a bona fide tumor suppressor and that its ability to favor ferroptosis by regulating glutaminolysis contributed to its tumor suppressive function.
[Cancer Research] |
|
|
|
| Scientists reported a mechanism of cell division control in the postnatal liver, in which Wnt/β-catenin signaling maintained active hepatocyte cell division through Tbx3, a Wnt target gene.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers reported a mechanism of cell division control in the postnatal liver, in which Wnt/β-catenin signaling maintained active hepatocyte cell division through Tbx3, a Wnt target gene.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Investigators reported hemochromatosis (HFE) as an oncogene in HCC and its undescribed function on promoting abscission in cytokinesis during mitotic cell division, independent of its iron-regulating ability.
[Oncogene] |
|
|
|
| The authors tested senescence markers in human hepatocytes subjected to chronic hyperinsulinemia in vitro and validated the data in vivo by using liver-specific insulin receptor knockout mice.
[Molecular Metabolism] |
|
|
|
| Elevated Rho guanine nucleotide exchange factor 2 (ARHGEF2) accelerated HCC angiogenesis via the EDN1 pathway, enhanced HCC cell proliferation and tumor growth both in vitro and in vivo, and contributed to endoplasmic reticulum (ER) stress-related treatment resistance.
[Cell Death & Disease] |
|
|
|
| Using a combination of in vitro and in vivo tools, investigators examined the role of hexokinase domain containing 1 (HKDC1) in liver cancer development and progression.
[Cell Death & Disease] |
|
|
|
| Scientists demonstrated that human umbilical cord mesenchymal stem cells treatment inhibited hepatic stellate cells activation, protected hepatocytes, and alleviate bile duct ligation-induced liver fibrosis in mice by up-regulating the expression of miR-148-5p and inhibiting the Notch signaling pathway.
[Stem Cell Research & Therapy] |
|
|
|
| Investigators showed that overexpression of SIRT7 promoted HCC cell migration and EMT while knockdown of SIRT7 showed opposite effects. Mechanistically, they found that SIRT7 suppressed E-Cadherin expression through FOXO3-dependent promoter binding and H3K18 deacetylation.
[Cancer Gene Therapy] |
|
|
|
| Based on 3D organoid culture of HCC-derived cell lines and AAV8-based protein overexpression in the mouse liver, the authors showed that activity modulation of isoform δ of phosphoinositide 3-kinase (PI3Kδ) controlled differentiation and discriminated between stemness and epithelial to mesenchymal transition (EMT).
[Communications Biology] |
|
|
|
| Due to the core role of liver cancer stem cells (LCSCs) in HCC metastasis and recurrence, researchers explored the RhoA-YAP1-autophagy pathway in LCSCs under fluid shear stress.
[Cell Adhesion & Migration] |
|
|
|
|
| The authors provide insight into technologies available to investigate the tumor microenvironment, and how such technologies are beneficial for improving our understanding of HCC carcinogenesis.
[Therapeutic Advances in Medical Oncology] |
|
|
|
| Scientists summarize the published clinical trials of stem cells for the treatment of liver fibrosis/cirrhosis and provide the latest overview of various cell sources, cell doses, and delivery methods.
[Stem Cell Research & Therapy] |
|
|
|
|
| MediciNova, Inc. announced the initiation of a Phase II clinical trial to evaluate MN-001 for the treatment of patients with non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus, and hypertriglyceridemia.
[MediciNova, Inc. (Globe Newswire, Inc.)] |
|
|
|
|
| October 24 – 26, 2022
Madrid, Spain |
|
|
|
|
|
| | Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
| | Mayo Clinic – Scottsdale, Arizona, United States |
|
|
|
| | Virginia Commonwealth University – Richmond, Virginia, United States |
|
|
|
| | Foundation for Liver Research – London, England, United Kingdom |
|
|
|
| | University of North Carolina at Greensboro – Kannapolis, North Carolina, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
